Liraglutide vs Retatrutide
Compare Liraglutide, Retatrutide: half-life, time to Cmax, dosing interval, published dose ranges and titration — citation-backed, research use only.
| LiraglutideSaxenda, Victoza | RetatrutideLY3437943View Retatrutide → | |
|---|---|---|
| Class | GLP-1 | GLP-1 |
| Route | Subcutaneous | Subcutaneous |
| Plasma half-life | 13 h | ~6.0 days (144 h) |
| Time to Cmax | 11 h | 36 h |
| Typical interval | Once daily | Once weekly |
| Published dose range | 0.6–3 mg | 2–12 mg |
| Titration ladder | 0.6 → 1.2 → 1.8 → 2.4 → 3 mg | 2 → 4 → 6 → 8 → 12 mg |
| Summary | Short-acting GLP-1 receptor agonist. Once-daily subcutaneous. Weekly dose escalation reduces nausea. | Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only. |
Source references
Liraglutide
- FDA Saxenda USPI — half-life ~13 h (2023)
- Pi-Sunyer X et al., NEJM 373:11 (2015)
Retatrutide
- Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023)
- Rosenstock J et al., Lancet 402:529 (titration arms) (2023)
For research use only. Not for human consumption. This tracker visualises only the doses you have logged or scheduled — it does not recommend dose sizes, does not suggest what to take, and is not pharmacokinetically calibrated. It is not medical advice and does not diagnose, treat, cure, or prevent any condition. Consult a licensed clinician before making any medical decision.